^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) + Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
868 Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study
Published date:
11/02/2023
Excerpt:
Adults with Ph+ CML-CP/AP without T315I treated with ≥2 prior TKIs and an ECOG performance status ≤2 were allocated to ASC + IMA, ASC + NIL, and ASC + DAS arms….Responses were achieved rapidly, with a median time to first MMR of 20.9, 20.1, and 22.1 wks in the ASC + IMA, ASC+ NIL, and ASC + DAS arms, respectively.
Trial ID:
